Literature DB >> 33628533

Aggressive Differentiated Thyroid Cancer due to EML4e13-ALKe20 Fusion: A Case Presentation and Review of the Literature.

Rodhan Khthir1, Zainab Shaheen1, Prasanna Santhanam2, Saroj Sigdel1.   

Abstract

BACKGROUND: Differentiated thyroid cancer (DTC) is an indolent malignancy. It rarely presents with aggressive local invasion and/or distant metastatic disease. Patient findings. We describe a case of a 30-year-old man with a locally aggressive form of papillary thyroid cancer with EML4e13-ALKe20 fusion (EML4: echinoderm microtubule-associated protein-like 4; ALK: anaplastic lymphoma kinase). He presented with right-side cervical lymphadenopathy with a highly suspicious right-side thyroid nodule. Total thyroidectomy and level IV lymph node resection showed extensive bilateral disease, with extrathyroidal and extranodal extension. FDG-PET CT scan following surgery confirmed the presence of significant residual disease in the neck area. He underwent bilateral lateral lymph node dissection followed by radioactive iodine treatment. Somatic mutation testing showed EML4e13-ALKe20 fusion. Summary. This case represents an aggressive form of DTC with EML4e13-ALKe20 fusion. The rapid progression of clinical signs and symptoms and the local extension beyond the thyroid and lymph nodes with the persistence of high-volume local disease after thyroidectomy highlight the aggressive nature of this mutation and the importance of performing genetic analysis to guide future treatments and determine prognosis.
CONCLUSION: This case highlights the importance of using molecular diagnostics in patient care, especially if the presentation is unusual for DTC. A thorough evaluation of the tumor pathology and the somatic mutational profile analysis are important for obtaining vital therapeutic and prognostic guidance.
Copyright © 2021 Rodhan Khthir et al.

Entities:  

Year:  2021        PMID: 33628533      PMCID: PMC7899757          DOI: 10.1155/2021/8837399

Source DB:  PubMed          Journal:  Case Rep Endocrinol        ISSN: 2090-651X


  20 in total

Review 1.  Targeting anaplastic lymphoma kinase in lung cancer.

Authors:  Alice T Shaw; Benjamin Solomon
Journal:  Clin Cancer Res       Date:  2011-02-02       Impact factor: 12.531

2.  Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.

Authors:  Michael J Demeure; Meraj Aziz; Richard Rosenberg; Steven D Gurley; Kimberly J Bussey; John D Carpten
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

Review 3.  Genetic alterations defining NSCLC subtypes and their therapeutic implications.

Authors:  Larissa A Pikor; Varune R Ramnarine; Stephen Lam; Wan L Lam
Journal:  Lung Cancer       Date:  2013-08-20       Impact factor: 5.705

4.  Characterization of thyroid cancer driven by known and novel ALK fusions.

Authors:  Federica Panebianco; Alyaksandr V Nikitski; Marina N Nikiforova; Cihan Kaya; Linwah Yip; Vincenzo Condello; Abigail I Wald; Yuri E Nikiforov; Simion I Chiosea
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

5.  Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

Authors:  Tsuyoshi Takahashi; Makoto Sonobe; Masashi Kobayashi; Akihiko Yoshizawa; Toshi Menju; Ei Nakayama; Nobuya Mino; Shotaro Iwakiri; Kiyoshi Sato; Ryo Miyahara; Kenichi Okubo; Toshiaki Manabe; Hiroshi Date
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

6.  Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.

Authors:  Avaniyapuram Kannan Murugan; Mingzhao Xing
Journal:  Cancer Res       Date:  2011-05-19       Impact factor: 12.701

7.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

10.  Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.

Authors:  Ying-Hsia Chu; Lori J Wirth; Alexander A Farahani; Vânia Nosé; William C Faquin; Dora Dias-Santagata; Peter M Sadow
Journal:  Mod Pathol       Date:  2020-07-31       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.